The effect of prostate motion during hypofractionated radiotherapy can be reduced by using flattening filter free beams

Hunor Benedek1,2,*, Minna Lerner1, Per Nilsson1,2, Tommy Knöös1,2, Adalsteinn Gunnlaugsson1, Crister Ceberg2
1 Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
2 Department of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden

OBJECTIVE: Hypofractionated radiotherapy of prostate cancer reduces the overall treatment time but increases the per-fraction beam-on time due to the higher fraction doses. This increased fraction treatment time results in a larger uncertainty of the prostate position. The purpose of this study was to investigate the effect of prostate motion during flattening filter free (FFF) Volumetric Modulated Arc Therapy (VMAT) in ultrahypofractionation of prostate cancer radiotherapy with preserved plan quality compared to conventional flattened beams.

MATERIALS AND METHODS: Nine prostate patients from the Scandinavian HYPO-RT-PC trial were re-planned using VMAT technique with both conventional and flattening filter free beams. Two fractionation schedules were used, one hypofractionated (42.7 Gy in 7 fractions), and one conventional (78.0 Gy in 39 fractions). Pre-treatment verification measurements were performed on all plans and the treatment time was recorded. Measurements with simulated prostate motion were performed for the plans with the longest treatment times.

RESULTS: All the 10FFF plans fulfilled the clinical gamma pass rate, 90% (3%, 2 mm), during all simulated prostate motion trajectories. The 10MV plans only fulfilled the clinical pass rate for three of the trajectories. The mean beam-on-time for the hypofractionated plans were reduced from 2.3 min to 1.0 min when using 10FFF compared to 10MV. No clinically relevant differences in dose distribution were identified when comparing the plans with different beam qualities.

CONCLUSION: Flattening-filter free VMAT reduces treatment times, limiting the dosimetric effect of organ motion for ultrahypofractionated prostate cancer with preserved plan quality.

1. Introduction

Prostate cancer is the most common form of cancer among the male population in Europe. A large number of these patients are treated with external beam radiotherapy [1,2]. Treatment with curative intent is conventionally given in 2 Gy fractions to total doses in the range 74–80 Gy to the prostate, i.e. in 37–40 fractions over 7–8 weeks.

The large number of prostate cancer patients and the long treatment courses have raised the demand for more time efficient treatment methods. Over the last couple of years several studies have proposed that the α/β ratio for prostate cancer is low, suggesting a potential benefit for hypofractionation, thus shortening the course of treatment by several weeks [3]. This has recently been confirmed for intermediate risk prostate cancer in a large randomized study comparing moderately hypofractionated treatment regimens (3 Gy/fraction) with conventional fractionation [4]. Several studies have been set up to explore a more extreme hypofractionation, including a Scandinavian prospective randomized phase III trial (HYPO-RT-PC) [5]. This study compares a total dose of 42.7 Gy in 7 fractions (6.1 Gy/fraction) with 78.0 Gy in 39 fractions (2.0 Gy/fraction) for intermediate risk prostate cancer patients.

In the HYPO-RT-PC study, image guidance prior to every treatment fraction is mandatory. Three gold markers are implanted into the prostate before the CT scanning. Before each fraction, kV-images are taken and the gold markers are matched to the reference image set. The prostate is therefore considered to be in the correct position when every treatment session is started, limited by the uncertainty of the image matching process. Despite this, the prostate position can be affected during the treatment due to rectal activity, bladder filling, muscle clenching and general pelvic motion [6]. Several studies have
investigated this issue, trying to predict the occurrence and extent of the prostate movement [7,8].

Several independent studies, using different methods, have found similar prostate motion trajectories. There are six different prostate motion patterns described [9-13]. The pattern of an individual patient is unpredictable and any of the six motion patterns can occur during each fraction. In any case, the positional uncertainty increases with time [12-16]. The increased dose per fraction and thereby increased treatment time for hypofractionation could lead to larger positional uncertainty due to the prostate motion. Flattening filter free (FFF) beams, which have higher dose rates, might offer a solution in decreasing the treatment time per fraction for ultra-hypofractionation of prostate cancer. A number of planning studies have investigated the plan quality and treatment time of FFF beams for hypofractionation of prostate cancer [17-21]. Most of them have shown a decreased treatment time for FFF beams with preserved plan quality for hypofractionation but no time saving for conventional fractionation. Some of the studies perform a pre-treatment QA measurement to ensure the deliverability of the treatment plans. To our knowledge, no study has investigated the potential reduction in prostate motion effects during beam delivery due to the shorter treatment times.

The aim of this study was to investigate the effects of intrafractional prostate motion using ultra-hypofractionated treatments of prostate cancer with FFF beams.

2. Materials and methods

Nine prostate cancer patients from the HYPO-RT-PC trial were selected for the study. The patients were chosen based on prostate size (“small”, “medium” and “large”) in order to explore the difference in treatment delivery for different target volumes. Three patients were chosen at random from each size category. Five of the patients were originally treated in the conventional arm of the HYPO-RT-PC study and four in the hypofractionated arm. The CTV was defined as the prostate as seen on the CT with MRI guidance as stated in the trial protocol. The PTV was generated from the CTV with a 7-mm isotropic margin added. All selected patients were treated with a VMAT technique. This study was approved by the Regional Ethics Board of Lund, Sweden (EPN Lund, Dnr 2013/742).

Six VMAT plans were optimised for each patient. The original patient treatment plans were not used in this study. Three different beam qualities were studied, 10MV flattening filter free (10FFF) and 10MV flattening filter free (10FFF). Two plans were generated for each energy; one with the conventional fractionation (78 Gy in 39 fractions), and one with hypofractionation (42.7 Gy in 7 fractions). Optimisation objectives were individually set for each plan and beam quality to fulfil the dose constraints defined in the HYPO-RT-PC study protocol. To obtain optimal plans, the study protocols prioritised clinical objective list was used. The plans were considered optimal when a lower priority objective could not be improved without deteriorate a higher prioritised objective. All treatment plan optimisation was made in the Eclipse Treatment Planning system (TPS) version 13 (Varian Medical Systems). The dose calculation algorithm used was the Analytical Anisotropic Algorithm (AAA) version 10.0.28. All plans were made with a single 360° arc VMAT. A maximum dose rate was allowed for each beam quality; 600 MU/min for 10MV, 1400 MU/min for 6FFF and 2400 MU/min for 10FFF. The final plans were reviewed and approved as clinically acceptable by a senior radiation oncologist.

A pre-treatment verification measurement was performed for all treatment plans according to the clinical routine at the radiotherapy department in Lund. The measurement device used was the Delta4 phantom (ScandiDos, Uppsala, Sweden). The verification plans were delivered on a Varian TrueBeam linear accelerator (Varian Medical Systems, Palo Alto, USA). The measured and planned doses were compared using a global gamma evaluation [22]. The criteria for the gamma evaluation were (3%, 2 mm), (2%, 2 mm), (2%, 1 mm), and (1%, 1 mm), with a dose threshold of 15%.

During the verification measurements, the beam-on times were recorded from the verification system. The beam-on times were later compared for the different beam qualities.

Dose-volume parameters stated in the trial protocol were extracted to evaluate the treatment plan quality. The median and range of the DVH parameters were calculated for both treatment fractionation arms. The dose parameters were normalised to the prescribed target dose, 78.0 Gy for the conventional arm and 42.7 Gy for the hypofractionated arm. Both the homogeneity index (HI) and the conformity index (CI) were calculated to further explore and compare the quality of the different treatment plans [23,24]. HI and CI are described in the Supplementary text.

The impact of the intrafractional prostate motion was investigated for the patients with the longest treatment times. To simulate the motion, the Delta4 Phantom was mounted on the Hexamotion module (ScandiDos, Uppsala, Sweden). The motion data used consisted of six different motion patterns, (stable trajectory, continuous drift, persistent excursion, transient excursion, high-frequency excursions and erratic behaviour), derived from real patient prostate motions by Ng et al. [12]. The motion trajectories were converted with a Matlab (MathWorks, Inc.) program to fit the data format of the Hexamotion’s software. The trajectories used can be found in Supplementary figure 1. The selected treatment plans were delivered while the Delta4 was moved according to the motion patterns. As a reference, the plans were delivered in a static setting with the same origin as defined for the delivery under motion. At the start of each motion pattern, the target was in the correct position to mimic the clinical situation during image-guided radiotherapy. To study the influence of delay, the treatment was started at different times after the start of the motion sequence. For the persistent excursion trajectory the treatment delivery started after 60 s, as an estimated image evaluation time. The transient excursion motion pattern was investigated with different start times for 10MV and 10FFF in order to include the peak offset in both plans. For the 10MV treatment, the beam was started 175 s into the trajectory. The 10FFF plan was started after 200 s.

Since the data did not follow a normal distribution as evaluated by the Kolmogorov-Smirnov test, the Wilcoxon signed rank test was used to evaluate the statistical significance of any differences between the beam qualities. The level of significance was set to $\alpha = 0.05$. The Hodges-Lehmann median differences with 95% confidence intervals were calculated for 10FFF DVH parameters compared to those for 10MV.

3. Results

3.1. Treatment time

The measured beam-on times are presented in Fig. 1 for each combination of beam quality and fractionation scheme. All the conventional plans were delivered within one minute except for the 10MV plan, which was delivered in 1.1 min. The hypofractionated 10MV plans had a mean beam-on time of 2.3 min, ranging from 2.1 to 2.8 min. The hypofractionated flattening-filter free plans had a significantly shorter delivery time. The 6FFF plans had a mean beam-on time of 1.3 min (range: 1.2–1.6 min) and the 10FFF plans had a mean delivery time of 1.01 min (range: 1.00–1.04 min).

3.2. Plan quality

All treatment plans fulfilled the specified dose volume objectives as stated in the trial protocol, see Supplementary table 1. Small, clinically insignificant differences were seen in the DVH parameters for all different beam qualities. A summary of the median of all DVH parameters is presented in Table 1.

Regardless of fractionation scheme or beam quality, no significant
Table 1

| DVH parameter          | Objective | Median (range) 10MV | Conventional fractionation | Median (range) 10FFF | Median Difference [95% CI] | P-value |
|------------------------|-----------|---------------------|-----------------------------|----------------------|----------------------------|---------|
| CTV Mean               |           | 100.5 (100.3–100.6) | 100.5 (100.4–100.8)         | 0.12 [0.07,0.18]     | 0.02                       |
| CTV Min                | 19%       | 97.9 (95.7–98.7)   | 97.6 (91.8–983)             | −0.07 [−0.61,0.42]   | 0.65                       |
| PTV V95%               | 77%       | 92.5 (98.7–99.8)   | 99.2 (94.7–99.8)            | −0.23 [−0.74,−0.01]  | 0.06                       |
| Rectum V95%            | 44%       | 11.3 (6.2–14.7)    | 11.3 (6.0–14.8)             | 0.11 [−0.27,0.44]    | 0.65                       |
| PTV D90%               | 99%       | 95.7 (94.6–96.6)   | 95.2 (93.2–96.1)            | −0.46 [−0.96,−0.10]  | 0.02                       |
| Rectum V95%            | 35%       | 17.8 (11.7–23.6)   | 20.8 (11.3–25.9)            | 1.13 [0.19,2.87]     | 0.02                       |
| FH dx Max              | 70%       | 38.7 (27.1–51.9)   | 39.2 (33.0–44.5)            | −0.83 [−4.12,2.5]    | 0.91                       |
| FH sin Max             | 70%       | 43.2 (30.6–52.0)   | 41.7 (31.4–47.1)            | −2.04 [−4.98,0.90]   | 0.16                       |
| Rectum V85%            | 45%       | 22.6 (13.8–20.0)   | 28.6 (16.4–37.1)            | 2.39 [0.71,3.5]      | 0.04                       |
| Body Max               | 105%      | 103.9 (103.0–104.9)| 104.4 (103.6–105.4)         | 0.53 [0.11,0.92]     | 0.02                       |
| Body Mean              |           | 4.9 (3.4–5.9)      | 4.8 (3.4–5.5)               | −0.12 [−0.25,−0.03]  | 0.02                       |
| Body V1%               |           | 15.0 (10.7–16.7)   | 14.8 (10.5–15.8)            | −0.54 [−0.81,−0.2]   | 0.01                       |
| Body V3%               |           | 18.5 (13.8–20.0)   | 18.4 (13.7–19.2)            | −0.45 [−0.71,−0.22]  | 0.004                      |
| CI                     |           | 0.88 (0.87–0.91)   | 0.89 (0.88–0.91)            | 0.005 [0.001,0.012]  | 0.08                       |
| HI                     |           | 0.05 (0.04–0.06)   | 0.06 (0.05–0.08)            | 0.007 [0.002,0.012]  | 0.01                       |
| Delta4 phantom         |           | 100.8 (100.3–100.7)| 100.6 (100.3–100.8)         | 0.12 [0.01,0.16]     | 0.05                       |
| CTV Min                | 19%       | 98.7 (97.0–98.6)   | 97.5 (95.9–98.2)            | −0.49 [−1.32,−0.11]  | 0.01                       |
| PTV V95%               | 77%       | 99.6 (98.5–99.9)   | 99.4 (98.6–99.8)            | −0.14 [−0.38,0.04]   | 0.10                       |
| Rectum V95%            | 44%       | 11.4 (6.3–14.1)    | 11.1 (6.0–14.4)             | −0.04 [−0.47,0.28]   | 0.57                       |
| PTV D90%               | 99%       | 95.7 (94.2–96.4)   | 95.6 (94.5–96.2)            | −0.27 [−0.52,0.08]   | 0.07                       |
| Rectum V95%            | 35%       | 18.8 (12.0–23.4)   | 18.5 (11.8–24.7)            | 0.16 [−1.11,1.24]    | 1.00                       |
| FH dx Max              | 70%       | 37.6 (28.6–55.4)   | 41.1 (29.9–52.2)            | 0.59 [−2.83,5.50]    | 0.73                       |
| FH sin Max             | 70%       | 38.8 (32.0–49.0)   | 40.9 (32.5–52.3)            | −0.87 [−3.91,4.6]    | 0.82                       |
| Rectum V95%            | 45%       | 24.9 (17.1–31.6)   | 25.5 (17.8–35.9)            | 0.94 [−1.92,4.27]    | 0.43                       |
| Body Max               | 105%      | 103.7 (103.3–105.0)| 104.6 (103.4–105.8)         | 0.59 [−0.17,0.26]    | 0.13                       |
| Body Mean              |           | 4.9 (3.4–5.9)      | 4.8 (3.4–5.7)               | −0.01 [−0.07,0.02]   | 0.25                       |
| Body V1%               |           | 14.9 (10.5–16.9)   | 14.9 (10.3–16.3)            | −0.20 [−0.33,−0.06]  | 0.01                       |
| Body V3%               |           | 18.5 (13.8–20.0)   | 18.2 (13.5–19.4)            | −0.32 [−0.45,−0.28]  | 0.004                      |
| CI                     |           | 0.89 (0.88–0.91)   | 0.89 (0.88–0.92)            | −0.001 [−0.007,0.006]| 0.84                       |
| HI                     |           | 0.05 (0.05–0.07)   | 0.06 (0.05–0.07)            | 0.005 [0.002,0.008]  | 0.01                       |

3.4. The effect of prostate motion

Two of the motion patterns, the stable trajectory and the continuous drift, had a maximum shift of less than 1 mm in all directions. The ratio of gamma pass rates between static measurement and measurement under motion (Fig. 2) with these two trajectories were 100% for all gamma criteria except for the 10MV plan and the most rigorous one, (1%, 1 mm), which resulted in a gamma pass rate of 99.3%. Neither the stable trajectory nor the continuous drift showed any clinically relevant effects from a treatment delivery point of view.

For the persistent excursion trajectory, the 10MV plan, delivered in 2.5 min, resulted in a lower pass rate than the 10FFF plan for all gamma criteria settings (Fig. 2). It was only for (1%, 1 mm) that the 10FFF plan showed a pass rate lower than 100%, for this trajectory. This motion pattern resulted in the largest differences in the ratio of pass rates between the 10MV and 10FFF plans.

The transient excursion trajectory was the only one where the 10FFF plan proved to be somewhat more sensitive in terms of pass rate compared to the 10MV plan (Fig. 2).

The two remaining trajectories, the high-frequency excursion and Delta4 phantom. The results were evaluated with gamma analysis using four different global criteria: (3%, 2 mm), (2%, 2 mm), (2%, 1 mm), and (1%, 1 mm), respectively. The criteria for clinically acceptable plans at our radiotherapy department, i.e. (3%, 2 mm, 90% pass rate), were fulfilled by all plans with a pass rate ≥ 98.8%. No correlation was found between prostate size and gamma pass rate for any level of gamma criteria stringency. No statistically significant differences in pass rate between the different beam qualities were observed.

3.3. Treatment plan verification

All treatment plans were verified with measurements using the Delta4 phantom. The results were evaluated with gamma analysis using four different global criteria: (3%, 2 mm), (2%, 2 mm), (2%, 1 mm), and (1%, 1 mm), respectively. The criteria for clinically acceptable plans at our radiotherapy department, i.e. (3%, 2 mm, 90% pass rate), were fulfilled by all plans with a pass rate ≥ 98.8%. No correlation was found between prostate size and gamma pass rate for any level of gamma criteria stringency. No statistically significant differences in pass rate between the different beam qualities were observed.
the erratic behaviour pattern, showed very similar results in ratios of pass rates. The pass rate decreases rapidly for more stringent gamma criteria. These trajectories showed the lowest pass rate ratios for both 10MV and 10FFF with a slightly higher result for 10FFF (Fig. 2).

4. Discussion

In this study we have shown that using flattening filter free VMAT for ultrahypofractionation of prostate cancer shortens the treatment time by about 50% without any clinical deterioration of treatment plan.
quality with regard to dose volume parameters and plan delivery verification results. Other publications have also shown decreased beam-on times for FFF VMAT [17–20]. However, these studies use conventional fractionation or two arcs, resulting in overall longer treatment times compared to the single arc VMAT used in this study. Lechner et al. even reported a slight increase in treatment time for FFF VMAT in their study [21]. Considering the time to change from one arc to another, the treatment times will be even longer [19]. We have also shown that the FFF VMAT plans are better suited for ultrahypofractionation, potentially reducing the effect of prostate motion. To our knowledge, this is the first study confirming the benefit of FFF with regard to treatment delivery during prostate movement. Most treatment planning studies investigating clinical FFF plans utilise the original clinical plan, and re-optimise with the same objectives [20]. Using this strategy a potential improvement can be missed or even worse a plan quality deterioration can be incorrectly indicated. To avoid this, the objectives were altered until the best possible plan was obtained for both the FFF and FF beams in this study. However, no clinically significant differences between the FF and FFF plans were observed. All dose constraints in the HYPO-RT-PC protocol were fulfilled for all plans. An even more unbiased method for plan comparison is the Pareto front method [21,25,26]. In future investigations, especially for more complex targets, the Pareto front method will be explored.

The largest benefit regarding treatment time was for the 10FFF plans. The beam-on times were decreased by more than 50% compared to 10MV. Due to safety regulations, the gantry rotation speed is restricted to 1.0 min per full rotation. Without this restriction, a 10FFF treatment could theoretically be delivered in less than a minute. The treatment time decrease for the 6FFF plans were not to the same extent as for 10FFF and would therefore not be considered as a potential clinical choice. The 10FFF plans resulted in better pass rates for five of the six motion patterns compared to the 10MV plans. This is mainly due to the shorter treatment time and that the prostate is more likely to move with longer time between the imaging and positioning. Other studies come to similar conclusions, e.g. Reggiori et al. who emphasise the importance of keeping treatment times to a minimum, due to the risk of intra-fractional prostate motion [27]. It has been recommended that the patient should be repositioned if the duration from the initial positioning to the end of treatment exceeds 4 min [15]. The 10MV plans, with a beam-on time of up to 3 min, give significantly less time to review the positioning image. With the reduced beam-on time (1.0 min) for 10FFF plans, there is more time to review the positioning images. In conclusion, we have shown that hypofractionated radiotherapy for prostate cancer delivered using flattening-filter free VMAT can reduce treatment time with preserved treatment plan quality. The reduced treatment time results in more robust treatment plans with respect to organ motion. Our study suggests that 10FFF can be used advantageously for hypofractionated radiotherapy for prostate cancer.

Conflict of interest statement

The authors declare no conflict of interest.

Acknowledgements

We would like to thank the radiotherapy department at Skåne university hospital, Lund for letting us perform this study. We also like to thank Lee Ambolt for the thorough proofreading and remarking and Andre Haroldsson for treatment planning consultation. Last, we want to thank Paul Keall and Jin Ng, for sharing their prostate trajectory data.

Appendix A. Supplementary data

Supplementary data associated with this article can be found in the online version, at http://dx.doi.org/10.1016/j.jphro.2018.05.001.

References

[1] Borrás JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol 2011;101:46–50.
[2] Zhou CK, Check DP, Lortet-Tieulent J, Lavasanne M, Jemal A, Ferlay J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends and by age group. Int J Cancer 2016;138:388–400.
[3] Dau A, Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol 2012;51:963–74.
[4] Dehrnayl D, Syndikus I, Mossop H, Khoz V, Birdie A, Bloomfield D, et al. Conventional versus hypofractionated high-dose-rate iodine-125 brachytherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047–60.
[5] Wieland A, Gnuzauglur A, Wilmarn L, Tellenberg Karlsson C, Hoyer M, Lagerlund M, et al. Extreme hypofractionation versus conventionally fractionated radiotherapy for intermediate risk prostate cancer: early toxicity results from the Scandinavian randomized phase III trial “HYPO-RT-PC”. Int J Radiat Oncol Biol Phys 2010;77:968–9.
[6] Nederveen AJ, van der Heide UA, Dehnad H, van Meijlraar R, Hofman P, Lagendijk JJ. Measurements and clinical consequences of prostate motion during a course of radiotherapy. Clin Oncol 2012;24:460–5.
[7] Gladwish A, Pang G, Cheung P, D’Alimontte L, Deabreu A, Loblaw A. Prostatic displacement during extreme hypofractionated radiotherapy using volumetric modulated arc therapy (VMAT). Radiat Oncol 2014;9.
[8] Quon H, Loblaw DA, Cheung PCF, Holden I, Tang C, Pang G, et al. Intra-fraction motion during extreme hypofractionated radiotherapy of the prostate using pre- and post-treatment imaging. Clin Oncol 2012;24:655–61.
[9] Kuppermann N, Willoughby T, Mahadevan A, Djimel T, Weinstein G, Jani S, et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys 2013;87:508–14.
[10] Xie Y, Dajjaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2011;81:236–46.
[11] Langen KM, Willoughby TR, Meeks SL, Sanhanaman A, Cunningham A, Levine L, et al. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys 2008;71:1084–90.
[12] Ng JA, Booth J, Poulsen PR, Hedelius W, Worm ES, Eade T, et al. Kilovoltage intrafraction monitoring for prostate intensity modulated arc therapy: first clinical results. Int J Radiat Oncol Biol Phys 2012;83:665–51.
[13] Liu Y, Liu T, Yang W, Yang X, Zhukov A. The non-Gaussian nature of prostate motion based on real-time intrafraction tracking. Int J Radiat Oncol Biol Phys 2013;87:563–9.
[14] Ballhausen M, Hi M, Hegemann NS, Gunowidjaja U, Belka C. Intra-fraction motion of the prostate is a random walk. Phys Med Biol 2015;60:549–63.
[15] Cramer AK, Haile AG, Ogjenovic S, Doshi TS, Reilly WM, Rubinsteiin KE, et al. Real-time prostate motion assessment: image-guidance and the temporal dependence of intra-fraction motion. BMC Med Phys 2013;13:4.
[16] Adamsson J, Wu Q. Prostate intrafraction motion assessed using simultaneous KV fluoroscopy at MV delivery: adaptive strategies. Int J Radiat Oncol Biol Phys 2018;101:1323–30.
[17] Zwahlen DR, Lang S, Hrbacek J, Glanzmann C, Kloeck S, Najafi Y, et al. The use of photon beams of a flattening-filter free linear accelerator for hypofractionated volumetric modulated arc therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;83:1655–60.
[18] Alongi F, Cozzi L, Aracangeli S, Iftode C, Comito T, Villa E, et al. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiat Oncol 2013;8:417.
[19] Chung JB, Kim JS, Hoo V, Kim IA, Kang SW, Lee JW, et al. Comparison of VMAT-SABR treatment plans with flattening filter (FF) and flattening filter-free (FFF) beam for localized prostate cancer. J Appl Clin Med Phys 2015;16:372B.
[20] Gasic D, Ohlhues L, Brodin NP, Fog LS, Pommer T, Bangsgaard JP, et al. A treatment planning and delivery comparison of volumetric modulated arc therapy with or without flattening filter for gliomas, brain metastases, prostate, head/neck and early stage lung cancer. Acta Oncol 2014;53:1005–11.
[21] Lechner W, Kragl G, Georg E. Evaluation of treatment plan quality of IMRT and VMAT with and without flattening filter using Pareto optimal fronts. Radiother Oncol 2013;109:437–41.
[22] Low DA, Harms WB, Munic S, Purdy JA. A technique for the quantitative evaluation of dose distributions. Med Phys 1998;25:656–61.
[23] Paddick I. A simple scoring ratio to index the conformality of radiotherapeutic treatment plans. Technical note. J Neurosurg 2000;93(Suppl 3):199–22.
[24] Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol 2012;188:97–9.
[25] Gursu OA, Engstrom PS, Sjostrom D, Behrens CF, Karlsson A, Knoos T, et al. The feasibility of using Pareto fronts for comparison of treatment planning systems and delivery techniques. Acta Oncol 2009;48:233–7.
[26] Thor M, Benedek H, Knoos T, Engstrom P, Behrens CF, Hasse AK, et al. Introducing multiple treatment plan-based comparison to investigate the performance of gantry angle optimisation (GAO) in IMRT for head and neck cancer. Acta Oncol 2012;51:743–51.
[27] Reggiori A, Mancuso P, Tozzi A, Cantione MC, Castiglioni S, Lattuada P, et al. Cone beam CT pre- and post-daily treatment for assessing geometrical and dosimetric intrafraction variability during radiotherapy of prostate cancer. J Appl Clin Med Phys 2010;12:3371.